Log In
Print this Print this

Tyvaso, inhaled treprostinil (formerly Viveta)

  Manage Alerts
Collapse Summary General Information
Company United Therapeutics Corp.
DescriptionInhaled synthetic long-acting stable prostacyclin analog
Molecular Target Prostacyclin (IP) receptor (PGI2) (PTGIR)
Mechanism of Action 
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentMarketed
Standard IndicationHypertension
Indication DetailsTreat pulmonary arterial hypertension (PAH); Treat pulmonary arterial hypertension (PAH) associated with idiopathic pulmonary fibrosis (IPF)
Regulatory Designation U.S. - Orphan Drug (Treat pulmonary arterial hypertension (PAH))

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today